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Background: To assess the relationship between serial serum leptin levels in patients with acute myocardial
infarction (AMI) who received thrombolysis and the degree of coronary atherosclerosis, coronary reperfusion,
echocardiographic findings, and clinical outcome. 51 consecutive patients presenting with AMI were studied.
Clinical characteristics including age, sex, body mass index (BMI) and cardiovascular risk factors were recorded.
Serial serum leptin levels at the time of admission and subsequently at 0, 6, 12, 24, 36, 60 hours afterwards were
obtained. Coronary angiography was performed in 34 patients; the relation between serum leptin levels and
evidence of coronary reperfusion as well as the extent of coronary atherosclerosis according to the coronary artery
surgery study classification (CASS) were evaluated. Echocardiographic evaluation was performed in all patients. 36
matched patients were enrolled as control group who had serum leptin level 9.4 ± 6.5 ng/ml.
Results: The patients mean age was 50.5 ± 10.6 years. There were 47 males and 3 females. 37.1% were diabetics,
23.5% were hypertensive, 21.6% were dyslipidemic and 22.7% were obese (BMI≥ 30). Leptin concentrations (ng/ml)
increased and peaked at the 4th sample (36 hrs) after admission (mean ± SD) sample (1) =9.55 ± 7.4, sample (2)
=12.9 ± 8.4, sample (3) =13.8 ± 10.4, sample (4) =18.9 ± 18.1, sample (5) =11.4 ± 6.5, sample (6) =10.8 ± 8.9 ng/ml.
There was a significant correlation between serum leptin and BMI (r = 0.342; p= 0.03). Leptin levels correlated
significantly to creatine kinase level on the second day (r = 0.43, p≤ 0.01). Significant correlation of mean serum
leptin with the ejection fraction (P< 0.05) was found. No difference in timing of peak serum leptin between patients
who achieved coronary reperfusion vs. those who did not (p= 0.8). There was a trend for an increase in the mean
serum leptin levels with increasing number of diseased vessels. There was no correlation between serum leptin
levels and outcome neither during the hospitalization nor at 9 months follow up.
Conclusion: Serum leptin levels increase after myocardial infarction. Serum leptin level may be a predictor of the left
ventricular ejection fraction and the degree of atherosclerosis but not of coronary reperfusion.
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Leptin is the 16,000 Dalton protein product of the obes-
ity gene (ob) [1]. Leptin has a role in the body weight
maintenance in humans. It is released into the blood
stream, where it binds to leptin-binding protein and is
transported into the cerebrospinal fluid [2-5] and exerts
its major effect on the hypothalamus. The role of leptin
in coronary artery vasoreactivity has been raised in a
study by Sundell J et al. [6] in obese and non-obese
patients, suggesting that leptin might have a role in the
regulation of the myocardial blood flow. A preliminary
study in a small number of patients suggested that leptin
levels might increase with acute myocardial infarction
[7]. Leptin is found to have multiple roles in the cardio-
vascular system. A number of investigators suggested its
role as a vasoactive substance [7]. There is also some
evidence that leptin may have a role in obesity-related
hypertension [8]. In a human study, a correlation was
seen between the serum concentration of leptin and
blood pressure among patients with essential hyperten-
sion [9]. Leptin also may have a prothrombotic effect
[10]. This effect appears to be mediated through the
platelet leptin receptor. In a previous study we suggested
that TNF alpha may represent a modulator of leptin ac-
tion in the hypothalamus, such finding may have impli-
cation in the setting of acute myocardial infarction [11].
The aims of the current study were to evaluate serial
levels of serum leptin among patients presenting with
acute myocardial infarction (AMI) and whether there is
a correlation between leptin and coronary reperfusion as
well as with angiographic and echocardiographic data.
Methods
Study design
This study was conducted at Hamad General Hospital.
51 patients who were admitted to the Coronary Care
Unit with a diagnosis of acute coronary syndrome (ACS)
were studied; after written informed consent for partici-
pation in the study was obtained from participants. The
definition of ACS in this study is according to the defin-
ition for acute myocardial infarction by the joint com-
mittee of American College of Cardiology/European
Society of Cardiology [12]. Patients with major co-mor-
bid conditions including renal failure were excluded
from the study. Hamad Medical Corporation institu-
tional review board approved the study.
Baseline clinical characteristics including age, sex, car-
diovascular risk factors, and complete cardiovascular
physical examination findings were recorded. The mode
of administered therapy was also recorded. 49 patients
with ST elevation myocardial infarction (STEMI) were
given thrombolytic therapy with either metalyse, or
streptokinase [13]. Tow patients suffered non-ST eleva-
tion myocardial infarction (NSTEMI). None of thesepatients developed acute complication such as cardio-
genic shock or acute homodynamic disturbance. Height,
weight, body mass index, smoking habit, alcohol intake,
diabetes mellitus, hypertension, lipid profile including
serum cholesterol, high density and low density lipopro-
tein, and serum creatinine of patients were analyzed.
Measurements of serum creatinine kinase, creatinine
kinase-MB portion, troponin T levels were taken at the
time of admission (0 time) and subsequently at 6, 12, 24,
36, 60 hours afterwards. Full echocardiographic studies
were performed for all patients on the 2nd day of admis-
sion. Variables including left ventricular ejection fraction
(LV EF%), left ventricular end-systolic dimension (LVESD),
left ventricular end-diastolic dimension (LVEDD), left
atrial size, right ventricular dimension (RVD) and right
ventricular systolic pressure (RVSP) were all recorded.
Coronary angiography was performed in 36 patients as a
routine clinical check up. Extent of diseased vessels
involved; whether single vessel, two -vessel, or three-vessel
diseases, and whether re-canalization achieved (defined
non-invasively as rapid resolution of ST segment eleva-
tion reperfusion arrhythmias and chest pain resolution
after thrombolytic therapy or angiographically by the
evidence of non-occluded culprit coronary artery) were
recorded.
36 matched (age and BMI) stable cardiac patients with
the same age and sex were taken as a control group and
their data were collected from the cardiology out patient
department.
Biochemical analyses
Blood samples were collected in plain tubes from each
patient at the time of admission and then at 6, 12, 24,
36, 48, 60 and 84 hours. All samples were separated and
analyzed immediately with the exception of serum lep-
tin. Aliquots for serum leptin were stored at −80 °C until
the collection was completed. Leptin concentrations
were measured by ELISA method. Linco Research, Inc
USA supplied the reagents. The measuring range was
0.5–100 ng/ml. According to manufacturer the assay has
high correlation with their radioimmunoassay for human
leptin (r = 0.967), lower detection limit is 0.5 ng/ml and
the concentration variations (CVs) at concentrations of
3.2 ng/ml & 8.18 ng/ml were 5% & 3.0% respectively
[14]. Total cholesterol (TC), Triglycerides (TG) and
HDL-cholesterol (HDL-C) were determined enzymati-
cally by Hitachi 917, Roche, Mannheim, Germany. LDL-
cholesterol (LDL-C) was estimated among those with
TG concentrations< 4.5 mmol/l as TC - HDL-C - Tg/
2.2 [15]. Those with TG >4.5 mmol/l were measured
directly by reagents from the same manufacturer [16].
Between-run imprecision (CVs) for TC, TG & measured
LDL- C were 3.0%, 4.0% 2.0% and 2.0% respectively.
Troponin T & CKMB were measured immunochemically
Table 1 Clinical baseline characteristics compared with mean and peak leptin sample
Variables
Mean Leptin Peak Leptin
Normoleptinemia hyperleptinemia Normoleptinemia hyperleptinemia
N=13 (29.5%) N=31 (70.4%) N=5 (13.1%) N=33 (86.8%)
Sex Male 11(84.6%) 31(100.0%) 4(80.0%) 32 (97.0%)
Female 2(15.4%) 0(0.0) 1(20.0%) 1(3.0%)
Age group ≤50 years 7(53.8%) 17(54.8%) 2(40.0%) 17 (51.5%)
>50 years 6(46.2%) 14(45.2%) 3(60.0%) 16 (48.5%)
Diabetic Yes 8(61.5%) 9(29.0%) 5(100.0%) 10 (30.3%)
No 5(38.5%) 22(71.0%) 0(0.0) 23 (69.7%)
Hypertensive Yes 4(30.8%) 5(16.1%) 1(20.0%) 6(18.2%)
No 9(69.2%) 26(83.9%) 4(80.0%) 27(81.8 %)
Body mass index (Kg/m2) <25 5(45.5%) 2(6.9%) 2(40.0%) 3(10.0%)
25-30 4(36.4%) 19(65.5%) 3(60.0%) 18(60.0%)
>30 2(18.2%) 8(27.6%) 0(0.0) 9(30.0%)
High Cholesterol >5.2 mmol/l Yes 5(38.5%) 4(12.9%) 1(20.0%) 7(21.2%)
No 8(61.5%) 27(87.1%) 4(80.0%) 26(78.8%)
HDL* Abnormal (<1)mmolL 10(90.9%) 10(37.0%) 5(100.0%) 12(41.4%)
Normal(>1) mmol/L 1(9.1%) 17(63.0%) 0(0.0) 17(58.6%)
LDL ≤3.3 mmol/L 4(40.0%) 20(69.0%) 3(75.0%) 19(61.3%)
>3.3 mmol/L 6(60.0%) 9(31.0%) 1(25.0%) 12(38.7%)
Triglyceride ≤1.7 mmol/L 6(66.7%) 7(24.1%) 1(25.0%) 11(35.5%)
>1.7 mmol/L 3(33.3%) 22(75.9%) 3(75.0%) 20(64.5%)
MI type Anterior 8(66.7%) 19(61.3%) 4(80.0%) 19(59.4%)
Inferior 4(33.3%) 10(32.3%) 1(20.0%) 11(34.4%)
Non ST Elevation 0(0.0) 2(6.5%) 0(0.0) 2(6.3%)
Normo-leptinemia: serum leptin level for male = (3.8 ± 1.8 ng/ml), and for female (7.4 ± 3.7 ng/ml) with BMI range 18–25.
Hyperleptinemia: serum leptin level> (3.8 ± 1.87 ng/ml) for males, for females> (7.4 ± 3.77 ng/ml) with BMI range 18–25.
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tocols. Imprecision, between run (CVs), for troponin &
CKMB were 2% & 3% respectively [17].
Normal fasting level of serum leptin
Normal fasting ranges for serum leptin are directly cor-
related with the degree of adiposity, with BMI range 18–
25; serum leptin level for men (3.8 ± 1.8 ng/ml), and for
women (7.4 ± 3.7 ng/ml). Serum leptin level rises ap-
proximately 2.5 times faster in women per unit BMI as
compared to man. Keeping in mind that a diurnal
rhythm of serum leptin concentrations, the values being
20 to 40 percent higher in the middle of the night as
compared with daytime [18,19]. The peak shifts are in
parallel with shifts in the timing of meals [20].
Coronary angiography and echocardiographic analysis
Coronary angiography was performed according to the
standard Judkin technique femoral approach either on
admission or during the recovery period. Several viewsof each coronary artery were analyzed. The severity of
arterial stenosis (defined as maximal percent reduction
in luminal diameter) was determined according to visual
estimation using the coronary artery surgery study clas-
sification (CASS) study analysis. Significant coronary
stenosis was defined as a 70% lumen narrowing or>
than 50% lumen narrowing of the left main coronary ar-
tery. The extent of coronary artery disease was classified
as 1, 2 or 3 vessels according to number of major coron-
ary arteries with significant stenosis [21].
Transthoracic 2 dimensional echocardiography 3
megahertz, 5500 Hewlett Packard Sonos machine was
used for the study. Images were captured in the 5 stand-
ard views, parasternal long axis views, short axis view
and 4, 2 &3 chamber views according to criteria of
American society of echocardiography. The measure-
ment of left ventricular dimensions was performed from
2 dimensional targeted M-mode at end diastolic and end
systolic dimensions and subsequently LV ejection frac-
tion was calculated. Left atrial size at end systole was
Table 2 Echocardiographic & coronary angiographic characteristics compared with mean and peak leptin sample
Variables
Mean Leptin Peak Leptin
Normoleptinemia Hyperleptinemia Normoleptinemia Hyperleptinemia
N=13 N=31 N=5 N=33
L. Atrium 1.9-4.0 cm 10(76.9%) 19(63.3%) 3(60.0%) 22(68.8%)
>4.0 cm 3(23.1%) 11(36.7%) 2(40.0%) 10(31.3%)
LVEDD ≤5.6 cm 11(84.6%) 23(76.7%) 4(80.0%) 26(81.3%)
>5.6 cm 2(15.4%) 7(23.3%) 1(20.0%) 6(18.8 %)
RVD ≤3.0 cm 12(92.3%) 30(100%) 5(100.0%) 31(96.9%)
>3.0 cm 1(7.7%) 0(0.0) 0(0.0) 1(3.1%)
RVSP ≤30 mmHg 4(30.8%) 13(44.8%) 2(40.0%) 14(45.2%)
>30 mmHg 9(69.25%) 16(55.2%) 3(60.0%) 17(54.8%)
FS% ≤25% 6(46.2%) 12(40.0%) 3(60.0%) 17(53.1%)
>25% 7(53.8%) 18(60.0%) 2(40.0%) 15(46.9%)
EF% ≤45% 9(69.2) 16(53.3%) 1(20.0%) 13(40.6%)
>45% 4(30.8%) 14(46.7%) 4(80.0%) 19(59.4%)
No of vessels 1VD 4(57.1%) 6(37.5%) 2(50.0%) 8(50.0%)
2VD 3(42.9%) 6(37.5%) 2(50.0%) 4(25.0%)
3VD 0(0.0) 6(37.5%) 0(0.0) 4(25.0%)
Recanalisation Yes 7(87.5%) 15(71.4%) 4(80.0%) 15(75.0%)
(noninvasive assessment) No 1(12.5%) 6(28.6%) 1(20.0%) 5(25.0%)
Normoleptinemia: serum leptin level for male = (3.8 ± 1.8 ng/ml), and for female (7.4 ± 3.7 ng/ml) with BMI range 18–25.
Hyperleptinemia: serum leptin level> (3.8 ± 1.87 ng/ml) for males, for females> (7.4 ± 3.77 ng/ml) with BMI range 18–25.
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tricular dimensions were recorded from the parasternal
long axis view. Conventional Doppler measurements
were obtained using tricuspid inflow, mitral early and
late diastolic inflow velocities, volumetric relaxation
times were also recorded. Wall motion abnormalities
were recorded using 16 segment models [22].Statistical analysis
The data were analyzed by using the Statistical Packages
for Social Sciences [SPSS] version 19 [23]. Data wereFigure 1 Mean values of Serum leptin level (ng/ml) during the
course of AMI at different time points (P value 0.04 based on
repeated measures ANOVA).expressed as mean and standard deviation (SD) unless
otherwise stated; student t test was used to ascertain the
significance of difference between mean values of two
continuous variables and confirmed by non-parametric
Mann Whitney test. Fisher exact and Chi square test
were performed to test for difference in proportions of
categorical variable between two and more groups. The
Pearson’s correlation coefficient was used to evaluate the
strength association between two variables. The level of
P< 0.05 was considered as the cut off value for signifi-
cance. Repeated measures ANOVA utilized to test differ-
ences in serial leptin measures.Results
Baseline clinical characteristics of the studied patients
shown in Table 1. The mean age of patients was
50.5 ± 10.6 years. There were 47 males and 4 females.
37.1% had diabetes mellitus, 23.5% had hypertension,
21.6% had high cholesterol, and 22.7% were obese
(BMI ≥ 30). Thirty six matched (with age and BMI)
stable cardiac patients were taken as a control group.
The mean serum leptin level of the control group was
9.43 ± 6.5 ng/ml.
Table 2 shows echocardiographic and coronary angio-
graphic characteristics compared with mean and peak
serum leptin sample.
Figure 2 Serum leptin level by number of diseased vessels
(VD). (SVD=9.2, 2VD=12.0, 3VD=12.9 ng/ml, p=0.6).
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during the course of AMI at different time points. Lep-
tin concentrations (ng/ml) increased and peaked at
fourth reading (36 hrs) after admission and gradually
decreased thereafter (mean ± SD sample (1) =9.55 ± 7.4,
sample (2) = 12.9 ± 8.4, sample (3) =13.8 ± 10.4, sample
(4) =18.9 ± 18.1, sample (5) =11.4 ± 6.5, sample (6)
=10.8 ± 8.9) ng/ml, P value 0.04 based on repeated mea-
sures ANOVA.
There was a significant correlation between serum lep-
tin and BMI (r = 0.34; p= 0.03). Leptin levels also corre-
lated significantly with serum creatine kinase level on
the second day (r = 0.43, p ≤ 0.01). There was no differ-
ence in timing of peak serum levels between patients
who had evidence of coronary reperfusion compared to
those who did not achieve coronary reperfusion (p= 0.8),Table 3 Correlation between mean Leptin level and
variables of interest
Mean serum Liptin Peak serum Liptin







Mean CK 0.188 0.369*
BMI 0.287* 0.152
Mean CKMB 0.188 0.004
Age 0.122 0.038
Mean Troponin −0.295 −0.277
*Two sided p value less than 0.05.
LVEDD: left ventricular diastolic dimension, LVESD: left ventricular systolic
dimension, RVD: Right ventricular dimension, RVSP: right ventricular systolic
pressure, FS: fraction shortening, EF: ejection fraction.also there was no significant difference in mean serum
leptin level in patients with anterior MI vs. inferior MI
(mean ± SD= 11.71 ± 7, 9 vs.11.86 ± 6.6 ng/ml, p= 0.9) re-
spectively. However, there was significant correlation
with left ventricular ejection fraction, LVEF (r =−0.25,
p= 0.01). No significant correlation between mean serum
leptin and left atrial size (r =−0.09; p= 0.5), left ventricu-
lar systolic (r = 0.017, p= 0.9) or diastolic dimension
(r = 0.1; p= 0.47) were found.
Figure 2 shows that mean serum leptin, which appeared
to increase with the increase in the number of diseased
vessels (mean, SVD=9.2, 2VD=12.0, 3VD=12.9, p=0.6),
although this was not statistically significant.
Correlation between mean and peak leptin level and
variables of interest showed significant correlation of
mean serum leptin with the ejection fraction and body
mass index (P< 0.05), and significant correlation of cre-
atinine kinase with mean leptin level (P< 0.05)
(Table 3).
Discussion
Studies on the role of serum leptin in coronary artery
disease are scarce [24-34] (Table 4). To the best of our
knowledge, this study is among few studies that analyzed
the serial serum leptin levels in the setting of acute myo-
cardial infarction and the first that evaluated its correl-
ation with angiographic and echocardiographic findings
in this high-risk group.
In the United States population, increased leptin con-
centrations was significantly associated with increased risk
of myocardial infarction and stroke in men and women,
independent of traditional cardiovascular risk factors and
obesity status [36]. We have shown previously a significant
correlation between serum leptin and hs-CRP in stable
cardiac patients [37]. Study by Stangl et al. [38] concluded
that patients with coronary artery disease exhibited higher
serum leptin concentrations than controls matched for
age, gender & BMI, suggesting that leptin could contribute
to the development of cardiovascular disease, possibly via
activation of the sympathetic nervous system. The
Trp64Arg variant of the β-adrenoceptor did not influence
serum leptin levels [38]. Leptin might be a marker of risk
of coronary artery disease, at least in men, and contributes
to the risk profile in subjects with insulin resistance. Lep-
tin concentrations were significantly higher in diabetic
and coronary artery disease patients than in controls. Body
weight, serum triglyceride concentration and systolic
blood pressure were all significantly related to the
logarithm of the serum leptin concentration in stable cor-
onary artery disease patients [39]. Wallace et al. [40] docu-
mented that leptin is an independent risk factor for
coronary artery disease using data from the west Scotland
coronary prevention study. It has been suggests that leptin
might participate in the catabolic state leading to
Table 4 Studies on leptin in acute myocardial infarction
study patients conclusion
Hadi Khafaji et al.
2011 Qatarcurrent
study
87 pts: 51 AMI pts
+ 36 matched
control
Leptin level is significantly correlated with BMI, CK, and LVEF. But neither with the
type of MI (anterior vs. inferior) nor with the severity of angiographic findings and
other echocardiographic parameters.
Yan GT,et al. * 2005
China [28]
AMI and CS pts Leptin levels of both AMI & coronary atherosclerosis pts are significantly without a




58 patients with AMI Plasma leptin levels in diabetic pts are significantly in acute stage of AMI than
in the period of convalescence.
Wallander M,et al.
2008Sweden [29]
181 AMI Circulating levels of leptin on the first morning after an AMI are associated




40 obese and 40
non-obese men.
Leptinemia is associated with fasting glucose, triglyceride levels, CRP &




35 pts stable angina
+ 40 STEMI, + 30
control
S. leptin is significantly in both stable angina &STEMI groups. No significant
correlation between leptin levels & selected risk factors
Amasyali et al.
2006Turkey [25]
41 pts with AMI
have thrombolysis
Failure of reperfusion therapy with streptokinase is significantly in patients




94 pts with acute
ST EMI + 46 controls
leptin level is in patients with acute STEMI
Meisel et al.
2001 Isreal [26]
30 pts, AMI Leptin peaked on the 2nd day of hospitalization with a 2-fold from its baseline
level on admission (p< 0.02). On day 3, leptin levels, & were 46%, 9%,
&6% above baseline on days 3, 4 and 5, respectively.
Fujimaki et al.
2001 Japan [35]
21 AMI pts 15
control
Hypoleptinaemic AMI pts had significantly plasma LDH vs. normoleptinaemic pts.





High leptin (OR 8.97; 95% CI: 1.73-46.5) & cholesterol (OR 5.18; 95% CI: 1.34-20.0)
levels significant risk factors for AMI in a multivariate model




Early after the acute coronary event, leptinemia in persons with AMI statistically
positively correlated with concentration of interleukine-6 & subsequently of
markers of coronary lesion severity (cTnI).
*Article in Chinese, information taken from the abstract, ** Article in Czech information taken from the abstract.
AMI: acute myocardial infarction, STEMI: STelevation myocardial infarction, cTnI): cardiac troponin I. BMI: Body mass index, CK: creatinine kinase, LVEF: left
ventricular ejection fraction, HDL-C: high density lipoprotein cholesterol, LDH: lactate dehydrogenase, OR: odd rartio. CI confidence interval
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ive heart failure [41].
The current study demonstrates elevation of serum
leptin levels in the acute phase of myocardial infarction
and it peaks at 36 hours after admission (doubled).
Whether leptin is released from the myocytes or it acts
only as an acute phase reactant protein after its release
from adipose tissue, was the main issue of this project.
The fact that there was no earlier peak in serum leptin
in patients who had coronary reperfusion after thrombo-
lytic therapy compared to those who don’t achieve
reperfusion suggests that leptin is not released from the
myocytes and is mainly an acute phase reactant similar
to high sensitivity C- reactive protein. This finding is
concordant to the study in Poland, which included 35
patients with AMI and showed that plasma leptin levels
in diabetic patients were significantly higher in AMI
than in the period of convalescence. These findings sug-
gest that leptin may play an important role in themetabolic changes taking place during the first days of
AMI [24].
Correlating mean and peak serum leptin levels; serum
leptin is positively correlated with the extent of diseased
coronary vessels (1-, 2-, and 3 -vessel disease) (Figure 2),
although statistically not significant, expanding the study
sample may be confirmatory of this finding. Furthermore
no significant correlation with either evidence of coron-
ary re-canalization or with the type of MI (whether anter-
ior or inferior) was found. We observed a significant
correlation between serum leptin and LVEF with no sig-
nificant correlation with other echocardiographic find-
ings. Significant correlations were found between high
serum leptin level and BMI as was demonstrated by pre-
vious studies (Table 3), with no significant correlation to
other cardiovascular risk factor; diabetes, hypertension,
total cholesterol LDL, HDL or triglyceride in this
patients’ population. In contrast to our study which has
followed the leptin up to 60 hours after the onset of
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plasma leptin concentrations obtained at the time of ad-
mission and 6 hours afterwards in 41 AMI patients who
were treated with thrombolytic therapy. The investigators
found that failure of reperfusion therapy with streptokin-
ase was significantly higher in patients with admission
plasma leptin concentrations ≥14 ng/mL as compared to
patients with admission plasma leptin concentrations
<14 ng/m, i.e. hyperleptinemia decreased the chance of
successful reperfusion . Left ventricular ejection fraction
was slightly but significantly higher in patients with ad-
mission plasma leptin concentrations ≥14 ng/mL than in
patients with admission plasma leptin concentrations
<14 ng/m (p= 0.031) [25]. Another study involving 30
consecutive AMI patients with a similar profile to the
current one, showed that leptin levels reached its peak
on the second day of hospitalization, with a 2-fold in-
crease from baseline level on admission (p< 0.02). On
day 3, leptin levels declined, and were 46%, 9%, and 6%
above baseline on days 3, 4 and 5, respectively, suggesting
that leptin may have a role in the metabolic changes tak-
ing place during the first days after an AMI. [26].
The predictive power of leptin on cardiovascular dis-
ease was addressed in a report from the Quebec cardio-
vascular study[27], eighty-six patients who developed
ischemic heart disease were compared with referent
matched for a number of traditional cardiovascular risk
factor including body mass index. Leptin did not emerge
as a predictor in coronary artery disease. However, fun-
damental differences between the two studies, first and
most importantly, patients in our present study were all
proven first ever AMI cases according to newly defined
criteria [12], whereas in Quebec, the study group consti-
tuted a mixture of stable and unstable angina [27]. Fur-
thermore Fujimaki et al. [35] correlated serum leptin
with other myocardial infarction markers and interleukin
level in 15 aged-matched controls and found a signifi-
cant negative correlation between these two markers.
These studies again suggest that leptin may play an im-
portant role in the metabolic changes taking place dur-
ing the first days of myocardial infarction.Limitations of the study
Since this study included a small number of patients, the
result should be interpreted cautiously.Conclusion
Serum leptin acts as an acute phase reactant in AMI
patients. Significant correlation was found in mean
serum leptin level with BMI, CK, and LVEF. There was
no significant difference in mean serum leptin level in
patients with anterior vs. inferior infarction and statisti-
cally no significant correlations of serum leptin withseverity of angiographic findings and other echocardio-
graphic parameters.
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